pegcetacoplan: Clinical Trials

10 trials of pegcetacoplan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 1 active not recruiting, 1 recruiting, 1 withdrawn. 10 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 310Completed 7, Active not recruiting 1, Recruiting 1, Withdrawn 1

Follow pegcetacoplan: new trials by email Literature Review of pegcetacoplan trials Research Report on pegcetacoplan

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients
Pegcetacoplan - C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN), Recurrent Glomerular Disease After Kidney Transplantation
Phase 3RecruitingSwedish Orphan Biovitrum302027-01-212026-11-09
Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
Pegcetacoplan, Placebo - Delayed Graft Function, End Stage Renal Disease
Phase 3WithdrawnApellis Pharmaceuticals, Inc.2026-05-182026-09-02
Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe
APL-2, Pegcetacoplan - Geographic Atrophy Secondary to Age-related Macular Degeneration
Phase 3CompletedApellis Pharmaceuticals, Inc.442025-10-242025-12-17
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Pegcetacoplan - C3G, IC-MPGN
Phase 3Active not recruitingApellis Pharmaceuticals, Inc.1002023-05-292026-04-02
A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)
Pegcetacoplan, Placebo matching Pegcetacoplan - Cold Agglutinin Disease
Phase 3CompletedSwedish Orphan Biovitrum242022-10-202025-10-30
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Pegcetacoplan, Placebo - C3G, IC-MPGN
Phase 3CompletedApellis Pharmaceuticals, Inc.1242021-11-122026-01-29
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
PEGCETACOPLAN (APL-2) - Geographic Atrophy Secondary to Age-related Macular Degeneration
Phase 3CompletedApellis Pharmaceuticals, Inc.7922021-03-042026-10-28
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
APL-2, Sham Procedure - Geographic Atrophy
Phase 3CompletedApellis Pharmaceuticals, Inc.6372018-08-312023-07-06
Pegcetacoplan Long Term Safety and Efficacy Extension Study
Pegcetacoplan - PNH
Phase 3CompletedApellis Pharmaceuticals, Inc.1372018-08-272026-11-10
Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pegcetacoplan, Soliris - Paroxysmal Nocturnal Hemoglobinuria
Phase 3CompletedApellis Pharmaceuticals, Inc.802018-06-142022-03-25

Conditions studied

Geographic Atrophy (2)  ·  Glomerulonephritis, Membranoproliferative (2)  ·  Anemia, Hemolytic, Autoimmune (1)  ·  Delayed Graft Function (1)  ·  Hemoglobinuria, Paroxysmal (1)  ·  Kidney Failure, Chronic (1)  ·  Macular Degeneration (1)

Sponsors

Apellis Pharmaceuticals, Inc. (8)  ·  Swedish Orphan Biovitrum (2)

Countries

Spain (8)  ·  United Kingdom (8)  ·  United States (8)  ·  Canada (7)  ·  France (7)  ·  Germany (7)  ·  Australia (6)  ·  Brazil (6)  ·  Italy (6)  ·  Belgium (5)  ·  Japan (5)  ·  Netherlands (5)  ·  Czechia (4)  ·  Israel (4)  ·  South Korea (4)

Results publications

PMID 37707673, PMID 40720060, PMID 42133432, PMID 33730455, PMID 34445916, PMID 35796199, PMID 35869984, PMID 36055332, PMID 37314061, PMID 37865470, PMID 38315872, PMID 38573482, PMID 38593241, PMID 38722644, PMID 38727860, PMID 38814626, PMID 39079163, PMID 40285403, PMID 40388106, PMID 41337715, PMID 41533918

NIH funding

2023 (1)